52 related articles for article (PubMed ID: 20310016)
1. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y
Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016
[TBL] [Abstract][Full Text] [Related]
2. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease.
Vermeire S; Dubinsky MC; Rabizadeh S; Panetta JC; Spencer EA; Dreesen E; D'Haens G; Dervieux T; Laharie D
Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102374. PubMed ID: 38750934
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a novel therapeutic drug monitoring-based nomogram for prediction of primary endoscopic response to anti-TNF therapy in active Crohn's disease.
Chen L; Kang D; Fang L; Sun M; Li M; Zhou G; Xu C; Pang Z; Ye Y; Feng B; Wu H; Lin J; Ding B; Liu C; Shi Y; Liu Z
Therap Adv Gastroenterol; 2024; 17():17562848241256237. PubMed ID: 38827646
[TBL] [Abstract][Full Text] [Related]
4. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study.
Biancone L; Orlando A; Kohn A; Colombo E; Sostegni R; Angelucci E; Rizzello F; Castiglione F; Benazzato L; Papi C; Meucci G; Riegler G; Petruzziello C; Mocciaro F; Geremia A; Calabrese E; Cottone M; Pallone F
Gut; 2006 Feb; 55(2):228-33. PubMed ID: 16120759
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study.
Esatoglu SN; Akkoc-Mustafayev FN; Ozguler Y; Ozbakır F; Nohut OK; Cevirgen D; Hamuryudan V; Hatemi I; Celik AF; Yazici H; Hatemi G
Front Immunol; 2020; 11():618973. PubMed ID: 33414791
[TBL] [Abstract][Full Text] [Related]
6. The impact of proactive versus reactive drug monitoring of infliximab on treatment outcomes in patients with crohn's disease.
Zhang Y; Jiang W; Xu C; Tian J; Chen J; Zhang H
Scand J Gastroenterol; 2024 Mar; 59(3):269-279. PubMed ID: 37991266
[TBL] [Abstract][Full Text] [Related]
7. Transient second-degree type 2 atrioventricular block after infliximab infusion in a patient with Crohn's disease and heterozygous familial hypercholesterolemia.
Jin Y; Wei W; Hou C; Liang Z; Wang J; Zhong H
Rev Esp Enferm Dig; 2024 Apr; 116(4):233-234. PubMed ID: 37771287
[TBL] [Abstract][Full Text] [Related]
8. Infliximab therapy decreases the expression of serum and faecal miR-126 and miR-20a in paediatric Crohn's disease: A pilot study.
Casertano M; Trotta MC; Cenni S; Creoli M; Miele E; Martinelli M; Lepre CC; Russo M; Alfano R; D'Amico M; Strisciuglio C
Acta Paediatr; 2024 Mar; 113(3):590-597. PubMed ID: 38140840
[TBL] [Abstract][Full Text] [Related]
9. Infliximab modifies CD74-mediated lymphatic abnormalities and adipose tissue alterations in creeping fat of Crohn's disease.
Shu W; Wang Y; Deji Z; Li C; Chen C; Ding W; Du P; Wang X
Inflamm Res; 2024 May; ():. PubMed ID: 38713235
[TBL] [Abstract][Full Text] [Related]
10. Adding Thiopurine After Loss of Response to Infliximab Versus Early Combination in Treating Crohn's Disease: A Retrospective Study.
Zeze K; Hirano A; Torisu T; Esaki M; Moriyama T; Umeno J; Kawasaki K; Fujioka S; Fuyuno Y; Matsuno Y; Kitazono T
Dig Dis Sci; 2021 Sep; 66(9):3124-3131. PubMed ID: 32920717
[TBL] [Abstract][Full Text] [Related]
11. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?
Argollo M; Kotze PG; Kakkadasam P; D'Haens G
Nat Rev Gastroenterol Hepatol; 2020 Nov; 17(11):702-710. PubMed ID: 32879465
[TBL] [Abstract][Full Text] [Related]
12. Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis.
Paul S; Marotte H; Kavanaugh A; Goupille P; Kvien TK; de Longueville M; Mulleman D; Sandborn WJ; Vande Casteele N
Clin Transl Sci; 2020 Jul; 13(4):743-751. PubMed ID: 32100960
[TBL] [Abstract][Full Text] [Related]
13. Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease.
Gomes LEM; da Silva FAR; Pascoal LB; Ricci RL; Nogueira G; Camargo MG; Lourdes Setsuko Ayrizono M; Fagundes JJ; Leal RF
Clinics (Sao Paulo); 2019 Apr; 74():e824. PubMed ID: 30994711
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
Khanna R; Levesque BG; Sandborn WJ; Feagan BG
Gastroenterol Hepatol (N Y); 2014 Aug; 10(8):478-489. PubMed ID: 28845139
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease.
Tighe D; McNamara D
World J Gastroenterol; 2017 Jan; 23(3):414-425. PubMed ID: 28210077
[TBL] [Abstract][Full Text] [Related]
16. The Role of Laboratory Tests in Crohn's Disease.
Cappello M; Morreale GC
Clin Med Insights Gastroenterol; 2016; 9():51-62. PubMed ID: 27656094
[TBL] [Abstract][Full Text] [Related]
17. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.
Kopylov U; Seidman E
Therap Adv Gastroenterol; 2016 Jul; 9(4):513-26. PubMed ID: 27366220
[TBL] [Abstract][Full Text] [Related]
18. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study.
Iwasa R; Yamada A; Sono K; Furukawa R; Takeuchi K; Suzuki Y
BMC Gastroenterol; 2015 Aug; 15():103. PubMed ID: 26271624
[TBL] [Abstract][Full Text] [Related]
19. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.
Vande Casteele N; Khanna R; Levesque BG; Stitt L; Zou GY; Singh S; Lockton S; Hauenstein S; Ohrmund L; Greenberg GR; Rutgeerts PJ; Gils A; Sandborn WJ; Vermeire S; Feagan BG
Gut; 2015 Oct; 64(10):1539-45. PubMed ID: 25336114
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring in inflammatory bowel disease.
Kopylov U; Ben-Horin S; Seidman E
Ann Gastroenterol; 2014; 27(4):304-312. PubMed ID: 25331715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
